Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
Phase 3
Completed
NCT04205812
| Condition | Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Incyte Corporation |
|---|
| Status | Completed |
|---|
| Enrollment | 583 participants |
|---|
| Interventions | Retifanlimab, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel |
|---|
| Start date | Sep 11, 2020 |
|---|
| Completion date | Dec 15, 2023 |
|---|
| Results posted | Feb 6, 2025 |
|---|
Summary
The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
Overall Survival
up to 39.1 months · months
| Placebo + Chemotherapy | 13.4 months |
|---|
| Retifanlimab + Chemotherapy | 18.1 months |
|---|
| p-value | 0.0042 |
|---|
| Hazard Ratio (HR) | 0.75 (95% CI 0.60–0.93) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.